Clinical Trial

Mesotherapy Treatment of Irritable Bowel Syndrome

Study acronym: MESOCOLO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems. Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy. Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-07; most recent amendment 2025-05-27.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-04-04
Trial Details
NCT Number NCT06261320
Lead Sponsor Polyclinique de l'Europe
Conditions Inflammatory Bowel Diseases
Enrollment 27 participants
Start Date 2024-02-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-31